Authorized purpose: Aplio a550, Aplio a450, and Aplio a software V6.5 are mobile diagnostic ultrasound systems used to visualize structures and dynamic processes and provide diagnostic image information across fetal, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, transesophageal, musculoskeletal, laparoscopic, and thoracic or pleural applications.
Clinical role
Supports diagnostic ultrasound acquisition and review with B-mode, M-mode, Doppler, tissue imaging, shear-wave and strain elastography, SMI, three- and four-dimensional imaging, fusion, navigation, attenuation imaging, contrast imaging, and related modes. V6.5 adds or improves network storage, liver, lung, breast, fetal-heart, fusion, obstetric, and review workflows.
Images and patients
Ultrasound · Multi-region
Key limitation
Keep in mind: Use is limited to the listed diagnostic applications and appropriately trained or legally qualified users. Available probes, modes, and packaged features depend on the installed model and configuration; the FDA summary reports no clinical study for the V6.5 changes.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Aplio a550, Aplio a450, and Aplio a software V6.5 are mobile diagnostic ultrasound systems used to visualize structures and dynamic processes and provide diagnostic image information across fetal, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, transesophageal, musculoskeletal, laparoscopic, and thoracic or pleural applications.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Multi-region Input: Ultrasound echo and Doppler data acquired with compatible flat linear, convex, and sector probes operating at approximately 2 to 20 MHz; supported workflows can also use stored raw data and external system connections.
Who uses it?Intended users: Physicians or other legally qualified persons who have received appropriate training.
What does the software produce?Output: Diagnostic ultrasound images, Doppler and quantitative measurements, elastography and attenuation displays, three- and four-dimensional images, and feature-specific analysis results for qualified-user interpretation. Supported functions include automated initial contour tracing for left-ventricular wall-motion tracking and automatic ejection-fraction analysis.
What is its most important limitation?Key limitation: Use is limited to the listed diagnostic applications and appropriately trained or legally qualified users. Available probes, modes, and packaged features depend on the installed model and configuration; the FDA summary reports no clinical study for the V6.5 changes.
Clinical takeaway. Clinical role: Aplio a550, Aplio a450, and Aplio a software V6.5 are mobile diagnostic ultrasound systems used to visualize structures and dynamic processes and provide diagnostic image information across fetal, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, transesophageal, musculoskeletal, laparoscopic, and thoracic or pleural applications.
Evidence takeaway. Evidence from the reviewed source record: FDA-reviewed support consists of manufacturer verification and validation with phantoms and volunteer data. The summary reports no clinical study and no quantitative performance results for the V6.5 changes.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Aplio a550, Aplio a450, and Aplio a software V6.5 are mobile diagnostic ultrasound systems used to visualize structures and dynamic processes and provide diagnostic image information across fetal, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, transesophageal, musculoskeletal, laparoscopic, and thoracic or pleural applications.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Ultrasound echo and Doppler data acquired with compatible flat linear, convex, and sector probes operating at approximately 2 to 20 MHz; supported workflows can also use stored raw data and external system connections.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Diagnostic ultrasound images, Doppler and quantitative measurements, elastography and attenuation displays, three- and four-dimensional images, and feature-specific analysis results for qualified-user interpretation. Supported functions include automated initial contour tracing for left-ventricular wall-motion tracking and automatic ejection-fraction analysis.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Use is limited to the listed diagnostic applications and appropriately trained or legally qualified users. Available probes, modes, and packaged features depend on the installed model and configuration; the FDA summary reports no clinical study for the V6.5 changes.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
FDA-reviewed support consists of manufacturer verification and validation with phantoms and volunteer data. The summary reports no clinical study and no quantitative performance results for the V6.5 changes.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA-reviewed support consists of manufacturer verification and validation with phantoms and volunteer data. The summary reports no clinical study and no quantitative performance results for the V6.5 changes.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K212960 software V6.5 verification and validation
DesignManufacturer risk analysis and bench and software verification and validation using phantoms and volunteer data
PopulationAplio a550, Aplio a450, and Aplio a systems with the V6.5 feature set; volunteer count and composition were not reported
Scopeexact submission
Tested versionAplio a550, Aplio a450, and Aplio a software V6.5
IndependenceSponsor or vendor study
K212960
Regulatory verification and validation evidence; it does not establish comparative clinical outcomes or site-specific performance.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
FDA recall Z-0198-2023 includes Canon Aplio a550, a450, and Aplio a systems. If a Stress Echo protocol is not manually terminated, a subsequent examination may fail to save images or may assign images to the previous patient, potentially delaying treatment. FDA lists the recall as open and classified.
FDA source
Exact FDA submission
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Exact a-series model match. The FDA recall record does not identify software V6.5 and also includes Aplio i-series models, so confirm the affected system and version locally.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Ultrasound echo and Doppler data acquired with compatible flat linear, convex, and sector probes operating at approximately 2 to 20 MHz; supported workflows can also use stored raw data and external system connections.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Software V6.5 can transfer DICOM data through Tricefy Access, store raw data on network-attached storage, and share deidentified images through Apligate or Apligate Soft. Canon's current interoperability page lists IHE statements for Aplio a550, a450, and Aplio a software V4.0 or later.
Scope: Exact FDA submission. Confirm the IHE statement, DICOM services, network-storage configuration, deidentification behavior, and external-service terms for the exact installed model and build.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: On-premises mobile Aplio a550, Aplio a450, or Aplio a ultrasound system running software V6.5, with optional site-network and external-service connections for supported data-transfer workflows.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Diagnostic ultrasound images, Doppler and quantitative measurements, elastography and attenuation displays, three- and four-dimensional images, and feature-specific analysis results for qualified-user interpretation. Supported functions include automated initial contour tracing for left-ventricular wall-motion tracking and automatic ejection-fraction analysis.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Diagnostic ultrasound images, Doppler and quantitative measurements, elastography and attenuation displays, three- and four-dimensional images, and feature-specific analysis results for qualified-user interpretation. Supported functions include automated initial contour tracing for left-ventricular wall-motion tracking and automatic ejection-fraction analysis.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
On-premises mobile Aplio a550, Aplio a450, or Aplio a ultrasound system running software V6.5, with optional site-network and external-service connections for supported data-transfer workflows.
Software V6.5 can transfer DICOM data through Tricefy Access, store raw data on network-attached storage, and share deidentified images through Apligate or Apligate Soft. Canon's current interoperability page lists IHE statements for Aplio a550, a450, and Aplio a software V4.0 or later.
Exact FDA submission
Checked 2026-09-02
Confirm the IHE statement, DICOM services, network-storage configuration, deidentification behavior, and external-service terms for the exact installed model and build.
Canon Medical's cybersecurity page states that Canon imaging systems follow a software development life cycle governed by the NIST 800-53 Risk Management Framework adhering to Defense Health Agency certification requirements; FIPS 140-2 certified cipher standards; deny-all firewall configuration and near-real-time SIEM syslog export as premium offerings; a dedicated cybersecurity risk management team for threat intelligence monitoring, advisories and incident response; and published OS and third-party update policies. Vendor statement; no certification or test report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the page is on us.medical.canon, Canon Medical's own site (Canon Medical Systems USA), and describes Canon Medical imaging devices generally; the FDA applicant is Canon Medical Systems Corporation, named in the corporate name-change press release on the same domain. Regional page with general device claims; exact-release scope is not established.
Supports compatible linear, convex, and sector probes at approximately 2 to 20 MHz and B-mode, M-mode, Doppler, tissue imaging, elastography, SMI, three- and four-dimensional imaging, fusion, navigation, attenuation, contrast, and related modes.
exact submission · checked 2026-09-02
Confirm each probe, option, contrast indication, and clinical preset on the purchased configuration.
The FDA summary describes DICOM transfer through Tricefy Access, raw-data storage on network-attached storage, and deidentified image sharing through Apligate or Apligate Soft.
exact submission · checked 2026-09-02
Validate local routing, firewall rules, identity handling, storage, retention, and external-service terms before use.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
22Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda device recall, vendor interoperability, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-10-27 - Exact FDA submission
No public price or quote for the exact K212960 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Canon Aplio reimbursement CPT Medicare"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Ge Medical Systems Ultrasound and Primary Care Diagnostics
Authorized purpose: LOGIQ E10s is a general-purpose diagnostic ultrasound system supporting the labeled adult, pediatric, cardiac, vascular, abdominal, obstetric, small-organ, musculoskeletal, urologic, and procedural applications.
Ge Medical Systems Ultrasound and Primary Care Diagnostics
Authorized purpose: LOGIQ E10 is a general diagnostic ultrasound system for qualified users across fetal and obstetric, abdominal, gynecologic, pediatric, small-organ, breast, cardiac, vascular, musculoskeletal, urologic, transrectal, transvaginal, transesophageal, and intraoperative applications.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.